A Pilot Open-Label Clinical Trial of CPI-613 in Patients With Advanced Bile Duct Cancers
Phase of Trial: Phase I/II
Latest Information Update: 28 Aug 2017
At a glance
- Drugs CPI 613 (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- 14 Aug 2017 Planned End Date changed from 1 May 2017 to 1 Feb 2018.
- 14 Aug 2017 Planned primary completion date changed from 1 May 2017 to 1 Feb 2018.
- 06 Jun 2017 Results (n=14) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology